ArticleJournal of pharmacy & bioallied sciences2026
HPV DNA Test Alone and HPV DNA Test Combined with VIA as Screening Test for Cervical Cancer.
Article in Journal of pharmacy & bioallied sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer (CC) remains a leading cause of cancer-related deaths among women globally. Persistent infection with high-risk human papillomavirus (HPV) is the primary risk factor. This study aims to compare the diagnostic accuracy of the HPV DNA test alone versus in combination with visual inspection with acetic acid (VIA) for CC screening in Bangladesh. Methodology: A cross-sectional analytical study was conducted at the National Centre for Cervical and Breast Cancer Screening and Training, Bangabandhu Sheikh Mujib Medical University, Dhaka, from September 2023 to August 2024. A total of 400 women underwent HPV DNA testing, VIA, and colposcopy. Data were analyzed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Results: The mean participant age was 39.9 ± 7.4 years. The HPV DNA test identified 9 positive cases (2.25%), VIA identified 44 (11%), and the combined test detected 8 cases (2%). Colposcopy confirmed 10 cases (2.5%). VIA showed 100% sensitivity but a low positive predictive value (PPV) (22.7%). HPV DNA had 80% sensitivity, 99.7% specificity, and 88.8% PPV. The combined approach showed 80% sensitivity, 100% specificity, and 100% PPV, with 99.5% accuracy. Conclusion: Combining HPV DNA and VIA improves specificity and predictive value, making it a highly effective CC screening strategy in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.